ILMN (Illumina, Inc.) — AI Stock Analysis & Recommendation

Research of August 26, 2026 · Healthcare / Laboratory Analytical Instruments

TradeFlare's AI research teams rate ILMN a HOLD. The latest price is $271.17.

The research plan

• Entry: $224.84
• Time horizon: days

The scanner trigger suggests a short-term post-earnings drift, but the conflicting team signals and high risk warrant caution.

Why

The scanner trigger suggests a short-term post-earnings drift, but the conflicting team signals and high risk warrant caution. Catalysts to watch: Continued post-earnings drift if the initial momentum holds; Positive developments in Illumina's product pipeline or market adoption; Favorable shifts in analyst sentiment or broader market conditions. Key risks: Significant fundamental headwinds and overvaluation concerns; Direct competitive threats from companies like Roche; High inherent volatility and a deep historical drawdown.

What could push ILMN higher

• Continued post-earnings drift if the initial momentum holds.
• Positive developments in Illumina's product pipeline or market adoption.
• Favorable shifts in analyst sentiment or broader market conditions.

Key risks for ILMN

• Significant fundamental headwinds and overvaluation concerns.
• Direct competitive threats from companies like Roche.
• High inherent volatility and a deep historical drawdown.

What each AI research team found

Fundamental team: Bearish · valuation: overvalued

Illumina is currently overvalued given its negative earnings growth and elevated P/E ratios, despite its dominant market position and strong business model. The analyst consensus target price suggests a downside, and increasing competition adds further risk. A bearish stance is warranted until valuation multiples contract or earnings growth re-accelerates.

• Illumina's current P/E of 42.03 is significantly higher than the estimated fair P/E of 26.1x, indicating overvaluation.
• Revenue growth YoY is positive at 9.4%, but earnings growth YoY is negative at -9.4%, suggesting margin pressure or increased operating expenses.
• Analyst consensus target mean of $198.89 is approximately 11.5% below the current market price of $224.84, indicating limited upside and potential downside.

Technical team: Bullish

The overall assessment is bullish, driven by strong trend and pattern analysis indicating an uptrend and potential breakout. However, concerns regarding volume and momentum suggest a moderate conviction, implying a need for caution around current resistance levels.

• The stock is in a strong uptrend, trading above key moving averages and resistance levels, suggesting further upside potential.
• The stock is consolidating near resistance with below-average volume, suggesting a neutral outlook with potential for a pullback.
• Momentum indicators are mixed, with MACD showing some bullish signs while RSI is neutral and Stochastic is not yet confirming a strong upward move, suggesting a neutral outlook near resistance.

Sentiment team: Neutral

Illumina's sentiment is currently neutral, reflecting a balance between positive news, strong recent performance, and analyst upgrades, against persistent concerns about valuation, mixed analyst views, and insider selling. While social media sentiment leans positive, professional analyst sentiment and news coverage are more tempered, leading to a stable but not strongly directional outlook.

• Illumina's news sentiment is neutral, characterized by a mix of positive developments like a renewed credit line and strong stock performance, alongside ongoing discussions about its valuation and sector comparisons. (Score: 0.062)
• Illumina (ILMN) exhibits a predominantly positive sentiment driven by strong recent stock performance, a Zacks Rank #1 upgrade, and renewed financing flexibility, though concerns about past acquisitions and valuation persist. (Score: 0.15)
• Illumina's sentiment is neutral, balancing positive news regarding financing flexibility, strong clinical momentum, and a Zacks Strong Buy rating against mixed analyst ratings, significant insider selling, and competitive pressures.

Risk team: High

Illumina presents a high-risk profile due to its significant historical drawdown, high volatility, and substantial competitive threats from Roche, alongside business model vulnerabilities. The high short interest further amplifies downside risk, necessitating a cautious approach with a small position size and robust risk management.

• Deep 1-Year Drawdown & High Volatility: The stock has experienced a significant -70.23% drawdown over the past year, coupled with high annualized volatility (48.07% 20-day, 43.07% 60-day), indicating substantial price fluctuations and potential for large losses.
• Competitive Threat from Roche: Roche's AXELIOS 1 platform represents a direct and significant threat to Illumina's market share in instrument placements and consumables, potentially impacting its core revenue streams.
• Business Model Disruption & Macro Sensitivity: Illumina's reliance on recurring consumables revenue is vulnerable to macroeconomic downturns, inflation, and rising interest rates, exacerbated by geopolitical and regulatory risks, particularly in China.

ILMN at a glance

Market value	$41.3B
Price / earnings	50.7
Revenue growth (year over year)	4.9%
Profit margin	18.4%
Debt / equity	0.24

Every AI call on ILMN since June 4, 2026, and what happened next (9 calls) →

Research of August 26, 2026 · AI-generated analysis for educational purposes, can be wrong, not financial advice.